Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – Leerink Partnrs reduced their Q3 2024 EPS estimates for shares of Pyxis Oncology in a research report issued to clients and investors on Tuesday, October 15th. Leerink Partnrs analyst J. La. Rosa now anticipates that the company will post earnings per share of ($0.35) for the quarter, down from their previous estimate of ($0.28). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.07) per share. Leerink Partnrs also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.07) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($1.07) EPS.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04.
View Our Latest Analysis on Pyxis Oncology
Pyxis Oncology Trading Up 16.1 %
Shares of NASDAQ PYXS opened at $3.75 on Friday. Pyxis Oncology has a 1-year low of $1.35 and a 1-year high of $6.85. The stock’s 50-day moving average is $3.54 and its 200 day moving average is $3.78. The stock has a market cap of $222.83 million, a price-to-earnings ratio of -3.02 and a beta of 1.27.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of PYXS. Fullcircle Wealth LLC purchased a new position in shares of Pyxis Oncology during the second quarter valued at about $40,000. SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology in the 3rd quarter valued at approximately $58,000. The Manufacturers Life Insurance Company bought a new stake in shares of Pyxis Oncology during the second quarter valued at approximately $65,000. Cetera Advisors LLC purchased a new stake in Pyxis Oncology in the first quarter worth $100,000. Finally, Schulhoff & Co. Inc. lifted its position in Pyxis Oncology by 90.9% during the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock valued at $139,000 after buying an additional 20,000 shares during the period. Hedge funds and other institutional investors own 39.09% of the company’s stock.
Pyxis Oncology Company Profile
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Read More
- Five stocks we like better than Pyxis Oncology
- Health Care Stocks Explained: Why You Might Want to Invest
- Survey Reveals: America’s Most Coveted Businesses in 2024
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What does consumer price index measure?
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.